For example, the PI3Kb inhibitor GSK2636771 sensitized PTEN-null melanomas to both CTLA-4 and PD-1 inhibitors and promoted T-cell infiltration to enhance the antitumor activity in vivo (142). Here, CTLA4 is linked to melanoma.